GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Quick Ratio

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Quick Ratio : 30.08 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Great Novel Therapeutics Biotech & Medicals's quick ratio for the quarter that ended in Dec. 2023 was 30.08.

Great Novel Therapeutics Biotech & Medicals has a quick ratio of 30.08. It generally indicates good short-term financial strength.

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's Quick Ratio or its related term are showing as below:

ROCO:7427' s Quick Ratio Range Over the Past 10 Years
Min: 2.22   Med: 13.26   Max: 30.08
Current: 30.08

During the past 6 years, Great Novel Therapeutics Biotech & Medicals's highest Quick Ratio was 30.08. The lowest was 2.22. And the median was 13.26.

ROCO:7427's Quick Ratio is ranked better than
96.01% of 1554 companies
in the Biotechnology industry
Industry Median: 3.53 vs ROCO:7427: 30.08

Great Novel Therapeutics Biotech & Medicals Quick Ratio Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Quick Ratio Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial 2.22 12.66 5.80 20.87 30.08

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.80 3.34 20.87 16.14 30.08

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Quick Ratio

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Quick Ratio falls into.



Great Novel Therapeutics Biotech & Medicals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Great Novel Therapeutics Biotech & Medicals's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(485.454-6.161)/15.932
=30.08

Great Novel Therapeutics Biotech & Medicals's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(485.454-6.161)/15.932
=30.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Great Novel Therapeutics Biotech & Medicals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines